# ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

> **NCT03923478** · PHASE1 · TERMINATED · sponsor: **Assembly Biosciences** · enrollment: 15 (actual)

## Conditions studied

- Ulcerative Colitis Chronic Mild
- Ulcerative Colitis Chronic Moderate

## Interventions

- **DRUG:** ABI-M201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03923478
- **Lead sponsor:** Assembly Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-24
- **Primary completion:** 2021-01-20
- **Final completion:** 2021-01-20
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2021-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03923478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03923478, "ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03923478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*